



AMERICAN COLLEGE OF SURGEONS

Inspiring Quality:
Highest Standards, Better Outcomes

100years

CQIP

Cancer Quality Improvement Program



Commission
on Cancer®

CQIP

Cancer Quality Improvement Program

St. Rita's Medical Center

6411560

Lima, OH



Annual Report 2013

American College of Surgeons: 100 Years of Quality Improvement




Commission on Cancer

- Established by the American College of Surgeons (ACoS) in 1922
- A consortium of professional organizations dedicated to improving survival and quality of life for cancer patients
- Sets standards to ensure quality, multidisciplinary, and comprehensive cancer care delivery in health care settings
- Conducts surveys to assess compliance with those standards
- Collects standardized data to measure cancer care quality
- Uses data to monitor treatment patterns and outcomes and enhance cancer control and clinical surveillance activities
- Develops educational interventions to improve cancer prevention, early detection, cancer-care delivery, and outcomes

National Cancer Data Base (NCDB)

- A joint program of the CoC and the American Cancer Society that began in 1988
- A nationwide oncology database for more than 1,500 CoC-accredited U.S. cancer programs
- 70 percent of all newly diagnosed U.S. cancer cases are captured at the facility level and reported
- Contains approximately 29 million records from hospital cancer registries across the U.S.

Commission on Cancer - Accredited Programs By State



Commission on Cancer: The Value of Accreditation

- **Demonstrates commitment** to patients, communities, providers, payers, and policymakers to improving survival and quality of life for patients and to evidence-based, organized, comprehensive, and quality cancer care
- **Standards ensure that state-of-the-art** clinical services for diagnosing, treating, rehabilitating, and supporting cancer patients and their families are available to provide **quality care**
- **National Cancer Data Base** participation by cancer registries captures more than 100 data elements for every patient and more than 70% of all new cancer patients diagnosed in the U.S. each year. Participant User File (PUF) access for research is only available to investigators at CoC-approved programs
- **Measuring quality and outcomes**, including overall survival, through a rapidly expanding panel of quality measures for cancers of the breast, colon, rectum, lung, esophagus, and stomach, and soon to include gynecologic and urologic malignancies, melanoma, sarcoma and pediatric tumors. Comparison with nation-wide data from all 1,500 CoC-accredited programs
- **Ensures a multidisciplinary team approach** including information and access to clinical trials, access to prevention and early detection programs, cancer conferences, and oversight by a Cancer Committee

Role of the Cancer Liaison Physician (CLP)

CLPs monitor the performance of their Cancer Program to address challenges and opportunities using information from the following NCDB Tools that include:

Accountability Measures

Quality Improvement Measures

Surveillance Measures

Survival Reports

Cancer Program Profile Practice Reports (CP3R)

Cancer Quality Improvement Program (CQIP)

Hospital Comparison Benchmark Reports (HCBM)

Rapid Quality Reporting System (RQRS)

Standard 4.3 *Role of the Cancer Liaison Physician - A Cancer Liaison Physician serves in a leadership role within the cancer program, and is responsible for evaluating, interpreting and reporting the program's performance using the National Cancer Data Base (NCDB) data. The CLP reports the results of this analysis to the cancer committee at least four times a year.*

CQIP – A Resource for the Cancer Liaison Physician Reporting to Cancer Committee

Cancer Quality Improvement Program (CQIP)

- A data-driven, process and outcomes-based cancer quality improvement initiative that confidentially reports to 1,500 individual CoC-accredited hospitals their data as entered in NCDB, including comparisons with national data from all CoC-accredited programs
- Web-based site accompanies the slide set providing information to support the reports, technical details, report creation, and scientific justification and references for quality measures
- Initial release provides CoC-accredited facilities with data on:
 - Compliance with CoC-adopted quality measures
 - Volume data for complex surgical oncology operations with 30-day mortality (if a minimum volume threshold is met)
 - Unadjusted survival data for selected cancer sites
 - Other clinical data and administrative data, which will be updated and expanded annually

Summary of CQIP 2013 Sections

- Cancer Program Volume (2009–2011)
- Cancer Program In/Out Migration (2007–2011)
- Quality Measure Reports
- Volume of Selected Complex Cancer Operations
- Thirty-Day Mortality after Selected Cancer Operations
- Unadjusted Survival Reports by Stage
- Breast Cancer—additional reports
- Colon Cancer—additional reports
- Non-Small Cell Lung Cancer (NSCLC)—additional reports
- Prostate Cancer—additional reports

Cancer Program Volume Reports


Cancer Program Volume

- Total Case Volume Over Time, 2009–2011
- Insurance Status (including national comparison)

Cancer Program In/Out Migration


- Total In/Out Migration, 2007-2011 - My Facility
- In/Out Migration by Insurance Status, 2011 - My Facility

Cancer Program Total Case Volume, 2009 - 2011 - My Facility




	2009	2010	2011
Colon	64	49	69
Rectum	11	10	12
Lung, Bronchus Non-Small Cell Carcinoma	92	94	82
Breast	158	141	140
Prostate	68	71	83
All Other Sites	338	303	343
Total	731	668	729

Insurance Status, 2009 - 2011 - My Facility vs. All CoC




	2009 My Facility	2010 My Facility	2011 My Facility	2011 All CoC
Not Insured	5.47 %	5.24 %	4.8 %	3.45 %
Private/ Managed	34.75 %	37.28 %	33.74 %	39.8 %
Medicaid	3.83 %	4.19 %	3.02 %	6.09 %
Medicare	54.58 %	51.65 %	56.93 %	45.43 %
Other Government	0.14 %	0.75 %	0.14 %	3.06 %
Insurance Status Unknown	1.23 %	0.9 %	1.37 %	2.17 %

Total In/Out Migration, 2007-2011 - My Facility



	2007	2008	2009	2010	2011
Diagnosed Here and Treated Elsewhere	8.03 %	5.44 %	5.47 %	7.34 %	9.47 %
Diagnosed and Treated Here	69.93 %	70.72 %	75.1 %	71.26 %	71.6 %
Diagnosed Elsewhere and Treated Here	22.04 %	23.84 %	19.43 %	21.41 %	18.93 %

In/Out Migration by Insurance Status, 2011 - My Facility



	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0.5 %	4.1 %	0.1 %	4.3 %	0 %	0.4 %
Diagnosed and Treated Here	3.8 %	24.4 %	2.2 %	40.1 %	0.1 %	1 %
Diagnosed Elsewhere and Treated Here	0.4 %	5.2 %	0.7 %	12.6 %	0 %	0 %

Quality Measure Reports

BREAST

- Post breast conservation irradiation (NQF 0219)
- Combination chemotherapy for hormone receptor negative (NQF 0559)
- Adjuvant hormonal therapy for hormone receptor positive (NQF 0220)
- Breast conserving surgery rate (surveillance measure)


COLON

- Adjuvant chemotherapy for lymph node positive (NQF 0223)
- At least 12 lymph nodes are removed and examined (NQF 0225)

RECTUM

- Radiation therapy with surgical resection (quality improvement measure)


BREAST, 2011: Post breast conservation irradiation (NQF 0219)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	100 %	93.5 %	94 %	94.3 %	91.5 %	91.1 %

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (CP3R data as of 11/7/2013)


BREAST, 2011: Combination chemotherapy for hormone receptor negative (NQF 0559)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	100 %	93.8 %	93.8 %	93.5 %	91.9 %	91.5 %

Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer. (CP3R data as of 11/7/2013)


BREAST, 2011: Adjuvant hormonal therapy for hormone receptor positive (NQF 0220)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	93.8 %	93 %	92.1 %	93.5 %	88.4 %	88.1 %

Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or Stage II or III hormone receptor positive breast cancer. (CP3R data as of 11/7/2013)


COLON, 2011: Adjuvant chemotherapy for lymph node positive (NQF 0223)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	100 %	92 %	92.7 %	92.7 %	89.5 %	88.6 %

Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer. (CP3R data as of 11/7/2013)


COLON, 2011: At least 12 lymph nodes are removed and examined (NQF 0225)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	96.6 %	87 %	88.8 %	87.8 %	87.4 %	87.7 %

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. (CP3R data as of 11/7/2013)


RECTUM, 2011: Radiation therapy with surgical resection (quality improvement measure)



	My Program	My State (OH)	My Census Region (East North Central)	My ACS Division (East Central)	My CoC Program Type (COMP)	All CoC Programs
Performance Rate	100 %	90.9 %	93.3 %	92.1 %	92.4 %	92.8 %

Radiation therapy is considered or administered within 6 months (180 days) of diagnosis for patients under the age of 80 of with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer. (CP3R data as of 11/7/2013)

Breast Conserving Surgery Rate - Patients with Clinical or Pathological Stage 0, I, II



BCS Rate	
2010 My Facility	75 %
2011 My Facility	62.86 %
2011 All CoC	60.85 %

Volume and 30-day Mortality After Selected Complex Cancer Operations


Volume of Selected Operations for Cancer

Cystectomy
Esophagectomy
Gastrectomy
Pancreatectomy
Rectal resection
Lung resection

30-day Unadjusted Mortality


Cystectomy
Esophagectomy
Gastrectomy
Pancreatectomy
Rectal resection
Lung resection

Number of Major Surgical Resections for Selected Cancers, 2009 - 2011 - My Facility



	Cystectomy	Esophagectomy	Gastrectomy	Rectal Resection	Pancreatectomy	Lung Resection
2009 Diagnosis Year	6	0	2	3	0	28
2010 Diagnosis Year	0	0	0	2	0	20
2011 Diagnosis Year	3	0	2	6	0	27

Unadjusted 30 Day Mortality by Surgical Procedure, 2009 - 2011 - My Facility vs. All CoC



	Cystectomy	Esophagectomy	Gastrectomy	Lung Resection	Pancreatectomy	Rectal Resection
All CoC	2.7 %	4.2 %	4.4 %	2.7 %	3.3 %	1.5 %
My Facility	*Too few cases	*Too few cases	*Too few cases	6.8 %	*Too few cases	*Too few cases

For statistical purposes, 30-day mortality data is only shown if 30 or more cases were performed over 3 years.

Unadjusted Survival Reports by Stage

Unadjusted Survival Rates by Stage

- Breast Cancer
- Colon Cancer
- Non–Small-Cell Lung Cancer
- Prostate Cancer



AMERICAN COLLEGE OF SURGEONS
*Inspiring Quality:
Highest Standards, Better Outcomes*


CQIP

Cancer Quality Improvement Program



© American College of Surgeons 2013—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.


Unadjusted 5 Year Breast Cancer Survival Rates by Stage, 2003 - 2006



	Stage 0	Stage I	Stage II	Stage III	Stage IV	OVERALL
My Facility	97.6 %	95.1 %	92.8 %	67.4 %	*Too few cases	89.1 %
All CoC	95.6 %	92.2 %	85.4 %	66.7 %	21.1 %	85.5 %

DISCLAIMER: (Includes patients of all ages, deaths from all causes, and there has been no adjustment for co-morbidities or other risk factors. If no result is shown, too few cases were submitted). Survival not calculated if less than 30 cases


Unadjusted 5 Year Colon Cancer Survival Rates by Stage, 2003 - 2006



	Stage 0	Stage I	Stage II	Stage III	Stage IV	OVERALL
My Facility	*Too few cases	81.8 %	69.7 %	62.6 %	3.1 %	57.8 %
All CoC	81.2 %	77.5 %	66.7 %	54.6 %	9.8 %	55.2 %

DISCLAIMER: (Includes patients of all ages, deaths from all causes, and there has been no adjustment for co-morbidities or other risk factors. If no result is shown, too few cases were submitted). Survival not calculated if less than 30 cases


Unadjusted 5 Year Non-Small Cell Lung Cancer Survival Rates by Stage, 2003 - 2006



	Stage I	Stage II	Stage III	Stage IV	OVERALL
My Facility	39.8 %	*Too few cases	7.7 %	2 %	12.6 %
All CoC	46.8 %	27.6 %	11.2 %	2.7 %	16.7 %

DISCLAIMER: (Includes patients of all ages, deaths from all causes, and there has been no adjustment for co-morbidities or other risk factors. If no result is shown, too few cases were submitted). Survival not calculated if less than 30 cases

Unadjusted 5 Year Prostate Cancer Survival Rates by Stage, 2003 - 2006




	Stage I	Stage II	Stage III	Stage IV	OVERALL
My Facility	*Too few cases	88.2 %	*Too few cases	*Too few cases	80.7 %
All CoC	83 %	90.8 %	91.1 %	37.6 %	87.9 %

DISCLAIMER: (Includes patients of all ages, deaths from all causes, and there has been no adjustment for co-morbidities or other risk factors. If no result is shown, too few cases were submitted). Survival not calculated if less than 30 cases

Breast Cancer—Additional Reports


- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Reported Race/Ethnicity
- Insurance Status
- Distance Traveled
- First Course Treatment – Stage I
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility
- Radiation Treatment After Breast Cancer Surgery Out Migration Heat Map By Zip Code

Stage Distribution - Breast Cancer Diagnosed in 2011, My Hospital vs. All CoC




	0	I	II	III	IV	NA	UNK
My Facility	20.71 %	38.57 %	23.57 %	7.86 %	3.57 %	0 %	5.71 %
All CoC	20.23 %	41.35 %	23.85 %	8.29 %	3.89 %	0.09 %	2.3 %

In/Out Migration Breast Cancer, 2009 - 2011 - My Facility




	2009	2010	2011
Diagnosed Here and Treated Elsewhere	5.06 %	4.96 %	11.43 %
Diagnosed and Treated Here	60.13 %	69.5 %	70.71 %
Diagnosed Elsewhere and Treated Here	34.81 %	25.53 %	17.86 %

In/Out Migration by Insurance Status Breast Cancer, 2011 My Facility




	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0 %	7.1 %	0 %	3.6 %	0 %	0.7 %
Diagnosed and Treated Here	2.9 %	35 %	3.6 %	29.3 %	0 %	0 %
Diagnosed Elsewhere and Treated Here	0 %	7.9 %	0 %	10 %	0 %	0 %

Reported Race/Ethnicity - Breast Cancer, 2011




	White	Black	Hispanic	Other/Unknown
My Facility	94.29 %	5 %	0 %	0.71 %
All CoC	77.53 %	11.65 %	5.52 %	5.29 %

Insurance Status - Breast Cancer, 2009 - 2011 My Facility vs. All CoC



	2009 My Facility	2010 My Facility	2011 My Facility	2011 All CoC
Not Insured	5.7 %	1.42 %	2.86 %	2.21 %
Private/ Managed	50.63 %	50.35 %	50 %	51.52 %
Medicaid	5.06 %	6.38 %	3.57 %	6.31 %
Medicare	37.97 %	39.72 %	42.86 %	36.64 %
Other Government	0 %	0.71 %	0 %	1.32 %
Insurance Status Unknown	0.63 %	1.42 %	0.71 %	2 %


Distance Traveled - Breast Cancer, 2011



	<=5 miles	6-10 miles	11-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	18.57	15.71	35.71	28.57	0.71	0.71	0
All CoC	18.23	22.32	30.9	13.76	5.79	3.09	5.9


First Course Treatment Stage I Breast Cancer, 2011

My Facility vs. All CoC




	Surgery Only	Surgery & Radiation	Surgery & Chemotherapy	Surgery, Radiation & Chemotherapy	Surgery, Radiation & Hormone Therapy	Surgery & Hormone Therapy	Surgery, Radiation, Chemotherapy & Hormone Therapy	Surgery, Chemotherapy & Hormone Therapy	Other Specified Therapy	No 1st Course Rx
My Facility	12.96 %	16.67 %	3.7 %	7.41 %	31.48 %	9.26 %	7.41 %	5.56 %	1.85 %	0 %
All CoC	15.56 %	9.29 %	5.8 %	5.97 %	31.88 %	16.2 %	6.73 %	3.95 %	2.24 %	1.52 %

Days to First Treatment Breast Cancer: Cases Diagnosed and Treated at My Facility, 2011




	1st Quartile (0-14 days)	2nd Quartile (15-27 days)	3rd Quartile (28-41 days)	4th Quartile (>= 42 days)
My Facility	23.38 %	45.45 %	23.38 %	7.79 %

Days to First Treatment Breast Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2011



	1st Quartile (0-14 days)	2nd Quartile (15-27 days)	3rd Quartile (28-41 days)	4th Quartile (>= 42 days)
My Facility	24.49 %	44.9 %	22.45 %	8.16 %

Zip Code Location of Radiation Delivery for Breast Cancer Heat Map, 2011




	At My Facility	Elsewhere	Total	Average Distance for All Pts
Patients Radiated	91.36% (n=74)	8.64% (n=7)	81	21.05

* n/d = Number of cases in zip code that received radiation in my facility / Number of cases in zip code that received radiation

Colon Cancer—Additional Reports


- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Reported Race/Ethnicity
- Insurance Status
- Distance Traveled
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility

Stage Distribution - Colon Cancer Diagnosed in 2011, My Hospital vs. All CoC




	0	I	II	III	IV	NA	UNK
My Facility	10.14 %	13.04 %	11.59 %	18.84 %	18.84 %	0 %	27.54 %
All CoC	5.94 %	19.77 %	24.38 %	24.57 %	19.27 %	0.16 %	5.91 %

In/Out Migration Colon Cancer, 2009 - 2011- My Facility




	2009	2010	2011
Diagnosed Here and Treated Elsewhere	4.69 %	2.04 %	7.25 %
Diagnosed and Treated Here	82.81 %	83.67 %	69.57 %
Diagnosed Elsewhere and Treated Here	12.5 %	14.29 %	23.19 %

In/Out Migration by Insurance Status - Colon Cancer, 2011 My Facility



	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0 %	4.3 %	0 %	2.9 %	0 %	0 %
Diagnosed and Treated Here	0 %	11.6 %	1.4 %	53.6 %	0 %	2.9 %
Diagnosed Elsewhere and Treated Here	1.4 %	2.9 %	0 %	18.8 %	0 %	0 %


Reported Race/Ethnicity - Colon Cancer, 2011



	White	Black	Hispanic	Other/Unknown
My Facility	92.75 %	5.8 %	0 %	1.45 %
All CoC	76.99 %	13.22 %	5.45 %	4.33 %


Insurance Status - Colon Cancer, 2009 - 2011

My Facility vs. All CoC




	2009 My Facility	2010 My Facility	2011 My Facility	2011 All CoC
Not Insured	3.13 %	10.2 %	1.45 %	3.57 %
Private/ Managed	34.38 %	24.49 %	18.84 %	31.45 %
Medicaid	3.13 %	8.16 %	1.45 %	5.08 %
Medicare	56.25 %	57.14 %	75.36 %	55.66 %
Insurance Status Unknown	3.13 %	0 %	2.9 %	1.75 %

Distance Traveled - Colon Cancer, 2011




	<=5 miles	6-10 miles	11-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	24.64	21.74	31.88	21.74	0	0	0
All CoC	21.23	22.59	27.51	12.2	6.21	3.71	6.55

Days to First Treatment: Colon Cancer Cases Diagnosed and Treated at My Facility, 2011



	2nd Quartile (0-6 days)	3rd Quartile (7-23 days)	4th Quartile (>= 24 days)
My Facility	66.67 %	24.24 %	9.09 %

Days to First Treatment: Colon Cancer Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2011




	2nd Quartile (0-6 days)	3rd Quartile (7-23 days)	4th Quartile (>= 24 days)
My Facility	60 %	24.44 %	15.56 %

Non-Small-Cell Lung Cancer (NSCLC)—Additional Reports


- Stage Distribution
- In/Out Migration Cancer
- In/Out Migration by Insurance Status
- Reported Race/Ethnicity
- Insurance Status
- Distance Traveled
- First Course of Treatment Stage I
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility

Stage Distribution - Non Small Cell Lung Cancer Diagnosed in 2011, My Hospital vs. All CoC




	0	I	II	III	IV	OC	NA	UNK
My Facility	0 %	26.83 %	12.2 %	24.39 %	35.37 %	0 %	0 %	1.22 %
All CoC	0.33 %	25.46 %	9.7 %	19.92 %	39.92 %	0.14 %	0 %	4.53 %

In/Out Migration Non-Small Cell Lung Cancer - My Facility, 2011




	2009	2010	2011
Diagnosed Here and Treated Elsewhere	3.26 %	13.83 %	14.63 %
Diagnosed and Treated Here	90.22 %	73.4 %	62.2 %
Diagnosed Elsewhere and Treated Here	6.52 %	12.77 %	23.17 %

In/Out Migration by Insurance Status Non-Small Cell Lung Cancer, 2011 - My Facility




	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	1.2 %	2.4 %	0 %	9.8 %	0 %	1.2 %
Diagnosed and Treated Here	7.3 %	13.4 %	2.4 %	37.8 %	0 %	1.2 %
Diagnosed Elsewhere and Treated Here	1.2 %	3.7 %	1.2 %	17.1 %	0 %	0 %

Reported Race/Ethnicity - Non-Small Cell Lung Cancer, 2011




	White	Black	Hispanic	Other/Unknown
My Facility	96.34 %	2.44 %	1.22 %	0 %
All CoC	81.97 %	11.33 %	3.16 %	3.54 %

Insurance Status - Non-Small Cell Lung Cancer, 2009-2011 My Facility vs. All CoC




	2009 My Facility	2010 My Facility	2011 My Facility	2011 All CoC
Not Insured	7.61 %	6.38 %	9.76 %	3.39 %
Private/ Managed	23.91 %	31.91 %	19.51 %	25.31 %
Medicaid	1.09 %	2.13 %	3.66 %	6.12 %
Medicare	66.3 %	57.45 %	64.63 %	59.62 %
Insurance Status Unknown	1.09 %	2.13 %	2.44 %	2.08 %

Distance Traveled - Non-Small Cell Lung Cancer, 2011




	<=5 miles	6-10 miles	11-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	15.85	17.07	19.51	43.9	3.66	0	0
All CoC	18.35	20.3	26.94	15.27	8.36	4.76	6.03

First Course Treatment Stage I Non-Small Cell Lung Cancer, 2011 My Facility vs. All CoC




	Surgery Only	Radiation Only	Surgery & Chemotherapy	Radiation & Chemotherapy	Chemotherapy Only	Surgery, Radiation & Chemotherapy	Other Specified Therapy	No 1st Course Rx
My Facility	54.55 %	4.55 %	4.55 %	0 %	4.55 %	9.09 %	0 %	13.64 %
All CoC	60.4 %	18.65 %	3.85 %	2.81 %	1.57 %	1.4 %	1.65 %	8.09 %

Days to First Treatment Non-Small Cell Lung Cancer: Cases Diagnosed and Treated at My Facility, 2011



	1st Quartile (0-9 days)	2nd Quartile (10-27 days)	3rd Quartile (28-47 days)	4th Quartile (>= 48 days)
My Facility	33.33 %	10 %	23.33 %	33.33 %

Days to First Treatment Non-Small Cell Lung Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2011




	1st Quartile (0-9 days)	2nd Quartile (10-27 days)	3rd Quartile (28-47 days)	4th Quartile (>= 48 days)
My Facility	31.82 %	9.09 %	22.73 %	36.36 %

Prostate Cancer—Additional Reports


- Stage Distribution
- In/Out Migration
- In/Out Migration by Insurance Status
- Reported Race/Ethnicity
- Insurance Status
- Distance Traveled
- First Course of Treatment Stage I and II
- Days to First Treatment: Cases Diagnosed and Treated at My Facility
- Days to First Treatment: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility

Stage Distribution - Prostate Cancer Diagnosed in 2011 My Hospital vs. All CoC




	I	II	III	IV	NA	UNK
My Facility	34.94 %	51.81 %	2.41 %	10.84 %	0 %	0 %
All CoC	23.43 %	57.06 %	10.15 %	6.15 %	0.03 %	3.18 %

In/Out Migration Prostate Cancer, 2011- My Facility




	2009	2010	2011
Diagnosed Here and Treated Elsewhere	0 %	0 %	1.2 %
Diagnosed and Treated Here	91.18 %	81.69 %	79.52 %
Diagnosed Elsewhere and Treated Here	8.82 %	18.31 %	19.28 %

In/Out Migration by Insurance Status Prostate Cancer, 2011 My Facility




	Not Insured	Private/Managed	Medicaid	Medicare	Other Government	Unknown
Diagnosed Here and Treated Elsewhere	0 %	0 %	0 %	1.2 %	0 %	0 %
Diagnosed and Treated Here	3.6 %	32.5 %	0 %	42.2 %	0 %	1.2 %
Diagnosed Elsewhere and Treated Here	0 %	2.4 %	0 %	16.9 %	0 %	0 %

Reported Race/Ethnicity - Prostate Cancer, 2011




	White	Black	Hispanic	Other/Unknown
My Facility	90.36 %	9.64 %	0 %	0 %
All CoC	75.9 %	15.36 %	4.59 %	4.15 %

Insurance Status - Prostate Cancer, 2009-2011 My Facility vs. All CoC




	2009 My Facility	2010 My Facility	2011 My Facility	2011 All CoC
Not Insured	2.94	4.23	3.61	2.12
Private/ Managed	30.88	38.03	34.94	45.1
Medicaid	1.47	2.82	0	2.57
Medicare	64.71	52.11	60.24	42.26
Other Government	0	2.82	0	5.79
Insurance Status Unknown	0	0	1.2	2.15

Distance Traveled - Prostate Cancer, 2011 - My Facility




	<=5 miles	6-10 miles	11-24 miles	25-49 miles	50-99 miles	>=100 miles	Unknown
My Facility	22.89	12.05	44.58	16.87	2.41	0	1.2
All CoC	14.02	17.84	28.48	16.13	9.47	8.15	5.91

First Course Treatment Stage I & II Prostate Cancer, 2011 My Facility vs. All CoC




	Surgery Only	Radiation Only	Surgery & Radiation	Radiation & Hormone Therapy	Surgery & Hormone Therapy	No 1st Course Rx
Stage I - My Facility	82.76 %	6.9 %	0 %	6.9 %	3.45 %	0 %
Stage I - All CoC	35.64 %	30.75 %	1 %	5.16 %	0.65 %	23.39 %
Stage II - My Facility	65.12 %	6.98 %	4.65 %	18.6 %	2.33 %	2.33 %
Stage II - All CoC	55.49 %	16.86 %	0.87 %	13.83 %	1.45 %	6.98 %

Days to First Treatment Prostate Cancer: Cases Diagnosed and Treated at My Facility, 2011



	1st Quartile (0-35 days)	2nd Quartile (36-62 days)	3rd Quartile (63-95 days)	4th Quartile (>= 96 days)
My Facility	47.46 %	30.51 %	10.17 %	11.86 %

Days to First Treatment Prostate Cancer: Cases Diagnosed at My Facility or Elsewhere; Treated at My Facility, 2011




	1st Quartile (0-35 days)	2nd Quartile (36-62 days)	3rd Quartile (63-95 days)	4th Quartile (>= 96 days)
My Facility	44 %	29.33 %	13.33 %	13.33 %

Commission on Cancer Member Organizations

- Academy of Nutrition and Dietetics (AND)
- Alliance for Clinical Trials in Oncology (ALLIANCE)
- American Academy of Hospice and Palliative Medicine (AAHPM)
- American Academy of Pediatrics (AAP)
- American Association for Cancer Education (AAE)
- American Cancer Society (ACS)
- American College of Obstetricians and Gynecologists (ACOG)
- American College of Oncology Administrators (ACOA)
- American College of Physicians (ACP)
- American College of Radiology (ACR)
- American College of Surgeons Resident and Associate Society (ACOSRAS)
- American College of Surgeons Young Fellows Association (ACOSYFA)
- American Head and Neck Society (AHNS)
- American Hospital Association (AHA)
- American Joint Committee on Cancer (AJCC)
- American Medical Association (AMA)
- American Pediatric Surgical Association (APSA)
- American Physical Therapy Association (APTA)
- American Psychosocial Oncology Society (APOS)
- American Radium Society (ARS)
- American Society of Breast Surgeons (ASBS)
- American Society of Clinical Oncology (ASCO)
- American Society of Colon and Rectal Surgeons (ASCRS)
- American Society of Plastic Surgeons (ASPS)
- American Society of Radiation Oncology (ASTRO)
- American Urological Association (AUA)
- Association of American Cancer Institutes (AACI)
- Association of Cancer Executives (ACE)
- Association of Community Cancer Centers (ACCC)
- Association of Oncology Social Work (AOSW)
- Cancer Support Community (CSC)
- Centers for Disease Control and Prevention (CDC)
- College of American Pathologists (CAP)
- Community Oncology Alliance (COA)
- Department of Defense (DOD)
- Department of Veterans Affairs (VA)
- Hematology/Oncology Pharmacy Association (HOPA)
- LIVESTRONG (Lance Armstrong Foundation)
- National Accreditation Program for Breast Centers (NAPBC)
- National Cancer Institute (NCI)
 - Applied Research Program
 - SEER Program
- National Cancer Registrars Association (NCRA)
- National Coalition for Cancer Survivorship (NCCS)
- National Comprehensive Cancer Network (NCCN)
- National Consortium of Breast Centers (NCBC)
- National Society of Genetic Counselors (NSGC)
- National Surgical Adjuvant Breast and Bowel Project (NSABP)
- North American Association of Central Cancer Registries (NAACCR)
- Oncology Nursing Society (ONS)
- Society of Gynecologic Oncology (SGO)
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- Society of Surgical Oncology (SSO)
- Society of Thoracic Surgeons (STS)

The American College of Surgeons and The American Cancer Society

Partners to Improve the Lives of Cancer Patients



The Commission on Cancer acknowledges the support of the American Cancer Society for their support of the National Cancer Data Base and the Cancer Liaison Physician Program



© American College of Surgeons 2013—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.

Acknowledgements

American College of Surgeons Commission on Cancer

Daniel P. McKellar, MD, FACS, Chair
David P. Winchester, MD, FACS, Medical Director, Cancer Programs

Commission on Cancer Committee Leadership 2012-2013

Accreditation

Linda W. Ferris PhD, Chair
Robert Sticca, MD, FACS, Vice-Chair

Cancer Liaison

Philip Y. Roland, MD, FACS, FACOG, Chair
Mary J. Milroy, MD, FACS, Vice-Chair

Education

Howard L. Kaufman, MD, FACS, Chair
Lisa Bailey, MD, FACS, Vice-Chair

Member Organizations

Virginia Vaitones, MSW, OSW-C, Chair
Katherine Hamilton, MA, RD, CDN, CSO, Vice-Chair

Quality Integration

Christopher M. Pezzi, MD, FACS, Chair
Lawrence N. Shulman, MD, Vice-Chair

CQIP

Christopher M. Pezzi, MD, FACS, CQIP Project Director
Kenneth Pristas, CQIP Project Manager, MSHI, PMP

CQIP/NCDB Staff

Greer Gay
Jeri Linn Philips
Florin Petrescu
Dennis Harman
Bryan Palis
Katherine Mallin
Kenneth Pristas

Further Assistance

Kenneth Pristas, MSHI, PMP
CQIP Project Manager
Phone: 312-202-5451
Email: kpristas@facs.org

CQIP Email

ncdbcqip@facs.org



AMERICAN COLLEGE OF SURGEONS

Inspiring Quality:
Highest Standards, Better Outcomes

100years

CQIP

Cancer Quality Improvement Program



Commission
on Cancer®

CQIP

Cancer Quality Improvement Program

Commission on Cancer

www.facs.org/cancer

312-202-5085

CQIP

www.facs.org/cancer/cqip